Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European <scp>LeukemiaNet</scp>Vincent H. J. van der Velden, Arjan van de Loosdrecht, Uta Oelschlaegel et al.|Cytometry Part B Clinical Cytometry|2021Cited by 44
Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the<scp>ELN iMDS</scp>flow working groupWolfgang Kern, Arjan van de Loosdrecht, Theresia M. Westers et al.|Cytometry Part B Clinical Cytometry|2022Cited by 30
Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS) - Composition of a Prognostic FCM-Score for Overall SurvivalUta Oelschlaegel, Shahram Kordasti, Aida Santaolalla et al.|Blood|2021Cited by 1
Diagnostic Application of Immunophenotypic Analysis of Erythroid Dysplasia in Myelodysplastic Syndromes. a Report on Behalf of the European Leukemianet-IMDS-Flow Cytometry Working GroupTheresia M. Westers, Arjan van de Loosdrecht, Eline M.P. Cremers et al.|Blood|2014Cited by 0
A COMPARISON OF PROGNOSTIC VARIABLES AND CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED AND 4738 WITH PRIMARY MDS INCLUDING THE INFLUENCE OF TREATMENT IN MDS-PHASEAndrea Kuendgen, Detlef Haase, Meritxell Nomdedéu et al.|Leukemia Research|2025Cited by 0